Literature DB >> 20981005

Assessing the clinical utility of diagnostics used in drug therapy.

J Woodcock1.   

Abstract

There is an ongoing debate over the evidentiary standards that should be applied for introduction of new diagnostics into routine clinical practice. Many call for evidence of "clinical utility," i.e., a positive impact on patient outcomes. A diagnostic, when used with a medicine, has clinical utility if it improves the outcomes of drug therapy. Improved outcomes may be defined broadly, including benefits, harm reduction, and patient-reported outcomes. Much of the controversy centers around the methods of demonstrating clinical utility. For instance, are randomized prospective trials the only acceptable source of data? Practically speaking, many sources of evidence-mechanistic, pharmacologic, and observational-can contribute to a finding of clinical utility, depending on the circumstances. Clinical utility is highly indication specific, and achieving it is dependent on good analytical and diagnostic test performance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20981005     DOI: 10.1038/clpt.2010.230

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Monitoring drug therapy.

Authors:  Thierry Buclin; Verena Gotta; Aline Fuchs; Nicolas Widmer; Jeffrey Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

Review 2.  Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response.

Authors:  Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum
Journal:  Nat Rev Drug Discov       Date:  2011-07-01       Impact factor: 84.694

Review 3.  The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?

Authors:  Mafalda M Dias; Michael J Sorich; Andrew Rowland; Michael D Wiese; Ross A McKinnon
Journal:  Pharm Res       Date:  2017-02-24       Impact factor: 4.200

Review 4.  An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.

Authors:  N A Meadows; A Morrison; D A Brindley; A Schuh; R W Barker
Journal:  Pharmacogenomics J       Date:  2014-10-07       Impact factor: 3.550

5.  The Berlin definition met our needs: no.

Authors:  Jesús Villar; Lina Pérez-Méndez; Robert M Kacmarek
Journal:  Intensive Care Med       Date:  2016-03-23       Impact factor: 17.440

Review 6.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

Review 7.  Genomics and drug response.

Authors:  Liewei Wang; Howard L McLeod; Richard M Weinshilboum
Journal:  N Engl J Med       Date:  2011-03-24       Impact factor: 91.245

8.  Pattern mixture models for clinical validation of biomarkers in the presence of missing data.

Authors:  Fei Gao; Jun Dong; Donglin Zeng; Alan Rong; Joseph G Ibrahim
Journal:  Stat Med       Date:  2017-05-02       Impact factor: 2.373

Review 9.  Biomarkers in reproductive medicine: the promise, and can it be fulfilled?

Authors:  Stephen S Palmer; Kurt T Barnhart
Journal:  Fertil Steril       Date:  2012-12-14       Impact factor: 7.329

Review 10.  Biomarkers, Early Diagnosis, and Clinical Predictors of Bronchopulmonary Dysplasia.

Authors:  Charitharth Vivek Lal; Namasivayam Ambalavanan
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.